Muhammad Khalid Khan Niazi
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Image Processing, Computer-Assisted | 14 | 2020 | 242 | 2.920 |
Why?
|
| Image Interpretation, Computer-Assisted | 6 | 2023 | 113 | 2.690 |
Why?
|
| Ki-67 Antigen | 4 | 2023 | 29 | 1.480 |
Why?
|
| Algorithms | 9 | 2022 | 468 | 1.240 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 680 | 1.050 |
Why?
|
| Cell Nucleus | 2 | 2018 | 109 | 1.030 |
Why?
|
| Neoplasms | 2 | 2023 | 628 | 1.010 |
Why?
|
| Lung | 2 | 2015 | 237 | 0.860 |
Why?
|
| Artificial Intelligence | 4 | 2023 | 49 | 0.820 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2019 | 47 | 0.820 |
Why?
|
| Microscopy | 2 | 2019 | 27 | 0.790 |
Why?
|
| Prognosis | 4 | 2024 | 1372 | 0.770 |
Why?
|
| Pathology | 1 | 2019 | 20 | 0.670 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 520 | 0.670 |
Why?
|
| Data Compression | 1 | 2018 | 2 | 0.660 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 21 | 0.620 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2020 | 179 | 0.610 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2015 | 7 | 0.600 |
Why?
|
| Neuroblastoma | 1 | 2017 | 32 | 0.580 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 133 | 0.560 |
Why?
|
| Proteomics | 1 | 2017 | 92 | 0.560 |
Why?
|
| Histocytochemistry | 1 | 2016 | 30 | 0.550 |
Why?
|
| Tuberculosis | 1 | 2015 | 14 | 0.520 |
Why?
|
| Humans | 24 | 2024 | 29552 | 0.520 |
Why?
|
| Neutrophils | 1 | 2015 | 102 | 0.500 |
Why?
|
| Granuloma | 1 | 2013 | 13 | 0.470 |
Why?
|
| Lymphocytes | 1 | 2013 | 55 | 0.460 |
Why?
|
| Abnormalities, Drug-Induced | 2 | 2010 | 4 | 0.460 |
Why?
|
| Software | 1 | 2013 | 110 | 0.440 |
Why?
|
| Information Storage and Retrieval | 3 | 2020 | 25 | 0.410 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 457 | 0.390 |
Why?
|
| Tympanic Membrane | 2 | 2020 | 6 | 0.370 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2010 | 1 | 0.360 |
Why?
|
| Teratogens | 1 | 2010 | 2 | 0.360 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2010 | 2 | 0.360 |
Why?
|
| Astemizole | 1 | 2010 | 2 | 0.360 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2010 | 9 | 0.360 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 59 | 0.350 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 727 | 0.350 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 208 | 0.330 |
Why?
|
| Phantoms, Imaging | 2 | 2018 | 56 | 0.310 |
Why?
|
| Female | 13 | 2023 | 18379 | 0.260 |
Why?
|
| Lymphoma, Follicular | 2 | 2017 | 19 | 0.260 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 210 | 0.260 |
Why?
|
| Cytokines | 2 | 2017 | 243 | 0.250 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 15 | 0.230 |
Why?
|
| Staining and Labeling | 2 | 2020 | 56 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 840 | 0.220 |
Why?
|
| Otoscopy | 1 | 2020 | 3 | 0.190 |
Why?
|
| Ear Diseases | 1 | 2020 | 6 | 0.190 |
Why?
|
| Otolaryngology | 1 | 2020 | 17 | 0.190 |
Why?
|
| Pattern Recognition, Automated | 2 | 2013 | 34 | 0.180 |
Why?
|
| Feasibility Studies | 2 | 2020 | 270 | 0.180 |
Why?
|
| Mice | 3 | 2015 | 2387 | 0.180 |
Why?
|
| Telemedicine | 1 | 2020 | 79 | 0.170 |
Why?
|
| Workflow | 1 | 2019 | 20 | 0.170 |
Why?
|
| Animals | 5 | 2015 | 7339 | 0.170 |
Why?
|
| Rosacea | 1 | 2019 | 46 | 0.160 |
Why?
|
| Interferon-gamma | 2 | 2015 | 51 | 0.160 |
Why?
|
| Antigens, Neoplasm | 1 | 2018 | 44 | 0.160 |
Why?
|
| Kidney | 1 | 2022 | 488 | 0.160 |
Why?
|
| Molecular Imaging | 1 | 2018 | 22 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2019 | 138 | 0.150 |
Why?
|
| Keratoconus | 1 | 2017 | 1 | 0.150 |
Why?
|
| Biopsy | 1 | 2018 | 243 | 0.150 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 796 | 0.140 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 116 | 0.140 |
Why?
|
| INDEL Mutation | 1 | 2015 | 10 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2018 | 576 | 0.140 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2015 | 46 | 0.130 |
Why?
|
| Prostate | 1 | 2016 | 69 | 0.130 |
Why?
|
| Chemokine CXCL5 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Chemokine CXCL2 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Chemokine CXCL1 | 1 | 2015 | 16 | 0.130 |
Why?
|
| Chemokines | 1 | 2015 | 35 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2017 | 523 | 0.130 |
Why?
|
| Observer Variation | 3 | 2020 | 96 | 0.130 |
Why?
|
| Necrosis | 1 | 2015 | 53 | 0.130 |
Why?
|
| Diabetic Retinopathy | 1 | 2015 | 64 | 0.130 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2015 | 142 | 0.120 |
Why?
|
| Hematoxylin | 1 | 2013 | 4 | 0.120 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2013 | 5 | 0.120 |
Why?
|
| Cell Count | 1 | 2013 | 51 | 0.120 |
Why?
|
| Host-Pathogen Interactions | 1 | 2013 | 31 | 0.120 |
Why?
|
| Embryo Culture Techniques | 2 | 2010 | 3 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2017 | 1172 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 1080 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 713 | 0.110 |
Why?
|
| Male | 7 | 2020 | 18012 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2013 | 71 | 0.110 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 984 | 0.100 |
Why?
|
| Image Enhancement | 2 | 2013 | 70 | 0.100 |
Why?
|
| Apoptosis | 1 | 2013 | 352 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2010 | 748 | 0.100 |
Why?
|
| Potassium Channel Blockers | 1 | 2010 | 9 | 0.090 |
Why?
|
| Cetirizine | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pregnancy | 2 | 2010 | 825 | 0.090 |
Why?
|
| Nitroimidazoles | 1 | 2010 | 4 | 0.090 |
Why?
|
| Embryonic Development | 1 | 2010 | 9 | 0.090 |
Why?
|
| Maternal Exposure | 1 | 2010 | 10 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 30 | 0.090 |
Why?
|
| Heart | 1 | 2010 | 165 | 0.090 |
Why?
|
| Rats | 2 | 2010 | 1609 | 0.080 |
Why?
|
| Heart Rate | 1 | 2010 | 316 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1389 | 0.070 |
Why?
|
| Handwriting | 1 | 2006 | 2 | 0.070 |
Why?
|
| Biometry | 1 | 2006 | 12 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 148 | 0.070 |
Why?
|
| Alleles | 2 | 2017 | 252 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 2 | 2017 | 214 | 0.070 |
Why?
|
| Child | 2 | 2023 | 2233 | 0.060 |
Why?
|
| Gene Expression | 2 | 2017 | 334 | 0.060 |
Why?
|
| Adult | 4 | 2020 | 8528 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 37 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2024 | 28 | 0.060 |
Why?
|
| Habits | 1 | 2023 | 3 | 0.060 |
Why?
|
| Breast | 1 | 2023 | 53 | 0.050 |
Why?
|
| Risk | 1 | 2023 | 293 | 0.050 |
Why?
|
| Health Personnel | 1 | 2023 | 111 | 0.050 |
Why?
|
| Logistic Models | 1 | 2023 | 729 | 0.050 |
Why?
|
| Video Recording | 1 | 2020 | 52 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 401 | 0.050 |
Why?
|
| Databases as Topic | 1 | 2020 | 24 | 0.050 |
Why?
|
| Alcohol Drinking | 1 | 2023 | 248 | 0.050 |
Why?
|
| Face | 1 | 2019 | 25 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 85 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 149 | 0.040 |
Why?
|
| Models, Biological | 2 | 2013 | 375 | 0.040 |
Why?
|
| Automation, Laboratory | 1 | 2017 | 3 | 0.040 |
Why?
|
| Entropy | 1 | 2017 | 8 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 152 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 185 | 0.040 |
Why?
|
| Pakistan | 1 | 2015 | 3 | 0.030 |
Why?
|
| Introns | 1 | 2015 | 40 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 735 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 225 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 533 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 489 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2015 | 200 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2013 | 107 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 574 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 4 | 0.030 |
Why?
|
| Diffusion | 1 | 2013 | 13 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 861 | 0.030 |
Why?
|
| Cell Communication | 1 | 2013 | 30 | 0.030 |
Why?
|
| Middle Aged | 2 | 2017 | 10936 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 864 | 0.030 |
Why?
|
| Cell Survival | 1 | 2013 | 278 | 0.030 |
Why?
|
| Phenytoin | 1 | 2010 | 4 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 692 | 0.020 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2010 | 13 | 0.020 |
Why?
|
| Bradycardia | 1 | 2010 | 15 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 199 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2010 | 81 | 0.020 |
Why?
|
| Computer Security | 1 | 2006 | 6 | 0.020 |
Why?
|
| Motion | 1 | 2006 | 11 | 0.020 |
Why?
|
| Online Systems | 1 | 2006 | 13 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 3128 | 0.020 |
Why?
|